title: CCL21 Cancer Immunotherapy.
abstract: Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.
authors.affiliation: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. yuanlin@mednet.ucla.edu.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. ssharma@mednet.ucla.edu.
authors.forename: Sherven
authors.initials: S
authors.lastname: Sharma
authors.affiliation: Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. mstjohn@mednet.ucla.edu.
authors.forename: Maie St
authors.initials: MS
authors.lastname: John